Fox Business - The Power to Prosper
Search Site

Novartis

Lilly CEO sees margins hitting pre-patent cliff levels by ‘19

Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.

Read More

  1. Who will be the number one pick in the NFL draft?

    The Vinnie from Queens panel weighs in on the NFL draft and the NBA playoffs.

  2. AstraZeneca Plans Spin-Offs

    AstraZeneca announced faster-than-expected progress of its experimental cancer drugs and plans to spin off billions of dollars of non-core assets as it staked a clai...

  3. Zimmer to Buy Biomet In $13.35B Deal

    Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...

  4. What the GSK, Novartis Deal Means for Biotech

    The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pha...

  5. What to expect from pharma

    Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.

  6. Pharma Deal Frenzy: A Bid to Boost Profits

    High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...

  7. Amgen Slumps After 1Q Earnings Miss

    Amgen (NASDAQ:AMGN) said Tuesday its first-quarter profit dropped 25% amid lower-than-expected sales for the biopharmaceutical firm.The company reported net income o...

  8. Novartis focusing on three giant areas

    Novartis CEO Joe Jimenez on his company’s corporate transformation and focus on pharmaceuticals, eyecare and generics.

  9. Big news in pharma

    Altaira senior managing director Ralph Acampora on the Novartis M&A news and the landscape for pharmaceuticals.

  10. Dow transports hit all-time high

    Altaira senior managing director Ralph Acampora on the Dow Transports and the ‘forgotten’ stocks to watch.

  11. U.S. futures look for direction

    FBN’s Maria Bartiromo on U.S. futures and the $25 billion in Novartis deals.

  12. European markets up

    WSJ Europe markets editor Charles Forelle says big pharma deals are boosting European markets.

  1. Developing technology for mobile devices

    InterDigital CEO William Merritt talks business in the technology industry.

  2. Novartis , Google join forces to create ‘smart’ contact lenses

    FBN’s David Asman on Novartis ’ partnership with Google, Facebook’s plans to track users’ TV habits and Morgan Stanley’s report on the potential Apple iWatch.

  3. Spending on pets surges

    Aratana Therapeutics CEO Steven St. Peter on what’s driving growth in the animal-health business.

  4. Eli Lilly CEO talks M&A

    Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.

  5. Ford CEO: I believe technology makes people better drivers

    Ford CEO Alan Mulally on technology in cars, the leadership transition at the automaker and balancing his work and family life.

  6. European PMI data mixed

    Markets.com chief economist Bill Hubard with the latest on the European markets.

  7. More M&A deals on the way?

    John Eade of the Argus Research Company and Mizuho chief investments strategist Carmine Grigoli discuss the M&A market and where the growth is.

‹ Prev12345Next ›
Freebase CC-BY
Source: Novartis on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL